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Abstract: Dermatitis herpetiformis (DH) is a common extraintestinal manifestation of coeliac disease
presenting with itchy papules and vesicles on the elbows, knees, and buttocks. Overt gastrointestinal
symptoms are rare. Diagnosis of DH is easily confirmed by immunofluorescence biopsy showing
pathognomonic granular immunoglobulin A (IgA) deposits in the papillary dermis. A valid
hypothesis for the immunopathogenesis of DH is that it starts from latent or manifest coeliac
disease in the gut and evolves into an immune complex deposition of high avidity IgA epidermal
transglutaminase (TG3) antibodies, together with the TG3 enzyme, in the papillary dermis. The mean
age at DH diagnosis has increased significantly in recent decades and presently is 40–50 years. The DH
to coeliac disease prevalence ratio is 1:8 in Finland and the United Kingdom (U.K.). The annual DH
incidence rate, currently 2.7 per 100,000 in Finland and 0.8 per 100,000 in the U.K., is decreasing,
whereas the reverse is true for coeliac disease. The long-term prognosis of DH patients on a gluten-free
diet is excellent, with the mortality rate being even lower than for the general population.
Keywords: dermatitis herpetiformis; coeliac disease; prevalence; epidermal transglutaminase;
gluten-free diet; long-term prognosis
1. Introduction
Dermatitis herpetiformis (DH) was described as a clinical entity by Louis Duhring in 1884,
four years before Samuel Gee published the symptoms of coeliac disease [1,2]. The hallmark of DH is the
symmetrical distribution of small vesicles and papules typically on the elbows, knees, and buttocks [3].
An intense itch is common, meaning that patients often scratch the vesicles. A breakthrough in the
accurate diagnosis of DH was the discovery of granular immunoglobulin A (IgA) deposits in the skin in
1969 [4]. Though patients with DH rarely presented with overt gastro-intestinal symptoms, small bowel
biopsies taken in the 1960s showed villous atrophy identical to that found in coeliac disease [5].
However, a quarter of the patients had normal small bowel villous architecture. Subsequently, it became
evident that these patients also had coeliac-type minor enteropathy, i.e., an increased density of
gamma/delta intraepithelial lymphocytes [6].
The rash in DH responds to a strict a gluten-free diet (GFD), albeit slowly, and the symptoms recur
on gluten challenge [7–9]. Therefore, a life-long GFD is the treatment of choice for all patients with
DH. Additionally, most patients initially receive dapsone (4,4-diaminodiphenylsulfone) medication,
which can be tapered off after a mean of two years’ strict adherence to a GFD [10].
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Genetic and family studies tie DH and coeliac disease closely together. Almost every patient with
DH and coeliac disease has the alleles contributing to the HLA-DQ2 or HLA-DQ8 haplotype [11].
These diseases segregate in the same families [12] and even monozygotic twin pairs can be affected by
DH and coeliac disease [13].
Clinical presentation of DH is not easy to recognize correctly by general practitioners and delay
of diagnosis for over two years occur in one third of the Finnish patients [14]. The presence of the
blistering rash with IgA deposits is the major difference between DH and coeliac disease. However,
other differences exist such as gender, age at onset, incidence, and long-term prognosis on a GFD.
These points will be discussed in more detail along with the immunopathogenesis of DH.
2. Clinical Presentation and Diagnosis of Dermatitis Herpetiformis
The typical sites of predilection of DH are the extensor surfaces of elbows and knees, and the
buttocks (Figure 1A,B). In addition, the upper back, abdomen, scalp and face can be affected, but oral
lesions are rare [3]. The rash is polymorphic with small blisters (Figure 1C). These are, however,
often eroded and crusted because of intense itch and scratching. Purpuric lesions may also appear on
the hands and feet, however, this is rare [3]. The presentation and activity of the rash varies greatly
from patient to patient, but complete remission is infrequent on a normal, gluten-containing diet.
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Figure 1. Dermatitis herpetiformis. Typical scratched papules and macules on the elbows (A), and on
the knees (B). Fresh small blisters on the elbow (C). Direct immunofluorescence showing granular IgA
deposits in the basal membrane zone between epidermis and dermis (D).
The clinical picture is often highly suggestive of DH, although, linear IgA bullous disease is
always a diagnostic problem [15]. Itchy skin disorders such as urticaria, atopic or nummular dermatitis,
and scabies infestation should be considered as a differential diagnosis [3]. The localization and
burning itch experienced during the development of blisters is, however, usually severe enough to
raise suspicion of DH. The typical histopathological findings in the lesional skin of patients with DH
consists of subepidermal vesicles associated with an accumulation of neutrophils at the papillary tips.
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The histopathology of a DH skin lesion is not diagnostic since other bullous diseases, such as linear
IgA bullous disease and epidermolysis bullosa acquisita, may show similar findings [16]. Moreover,
the histopathologic picture of DH is often unspecific revealing only perivascular lymphocytic infiltrate
and minimal inflammation in dermal papillae.
The ideal method for diagnosis of DH is a direct immunofluorescence biopsy of unaffected skin
in close proximity to an active lesion [17]. This reveals pathognomonic granular IgA deposits at the
dermo-epidermal junction (Figure 1D), and the diagnosis of DH should not be made without this
finding [16].
3. Gender and Age at Onset
Earlier studies in adults with DH have shown male to female ratios ranging up to 2:1 [3] with
two recent large DH studies finding the ratio to be close to 1:1 [18,19]. This is in sharp contrast to
coeliac disease, in which females outnumber males [20] (Table 1). This gender imbalance may reduce
with increasing age, and it has also been absent in some coeliac disease screening studies [21,22].
These findings suggest that gender differences between DH and coeliac disease are perhaps not as
profound as was earlier thought.
Coeliac disease can be diagnosed at any age with the peak incidences being in early childhood
and between 40 and 60 years of age [20,23]. Clinical series in adults with DH from Europe and North
America have shown that the mean age at diagnosis is between 40 and 50 years [14,24]. Like coeliac
disease, the oldest DH patients have been over 80 years of age at diagnosis. In contrast to coeliac
disease, DH in childhood seems to be rare; it was found in only 4% of 476 Finnish patients [25].
However, differences may exist. In an Italian series comprising 159 DH patients, 36% were below the
age of 20 years [26], and a large series of 127 Hungarian children with DH has been published [27].
A study of 477 patients collected from 1970 onwards in Finland showed a significant increase in
the mean age at diagnosis [18]. The increase was from 35 to 51 years in men and from 36 to 46 years
in women. A similar increasing trend in the mean age at diagnosis has also been observed in recent
decades in adult coeliac disease, both in Finland and elsewhere [28–30]. One explanation for this trend
may be changes in dietary habits, such as the consumption of wheat, which in Sweden has changed
the appearance of childhood coeliac disease [31]. In Finland, the annual consumption of wheat, rye,
and other cereals per person has decreased from 150 kg to 71 kg over the past 50 years [32]. A lower
lifetime gluten load might thus explain the increasing age at diagnosis and perhaps also the trend
towards less severe small bowel atrophy in DH and coeliac disease [33–35].
Table 1. Differences between dermatitis derpetiformis and coeliac disease.
Dermatitis Herpetiformis Coeliac Disease
Gender Slightly more males Females predominate
Age at onset Mainly adults Children and adults
IgA-TG3 deposits in the skin 100% 0%
Small bowel villous atrophy 75% 100% *
IgA-TG2 deposits in the small
bowel mucosa [36,37] 80% up to 100% **
Prevalence in Finland and
United Kingdom [18,19,38] 75 and 30 per 100,000 660 and 240 per 100,000
Incidence Decreasing Increasing
Response to a gluten-free
diet [7,8,20]
Slow; months, in the beginning most
patients need dapsone to control the rash
Rapid; days or weeks until gastro-intestinal
symptoms end whereas small bowel villous
atrophy may persist for many years
Long-term prognosis on
a gluten-free diet [39–41] Excellent
All-cause and lymphoma mortality may
be increased
TG3 = epidermal transglutaminase, TG2 = tissue transglutaminase; * Potential coeliac disease with normal small
bowel mucosa architecture, inflammation and positive TG2 serology also exist; ** Data still sparse.
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4. Prevalence and Incidence
Two recent large DH studies with a total of 477 and 809 patients found a prevalence of 75.3 per
100,000 in Finland and 30 per 100,000 in the U.K., respectively [18,19] (Table 1). In the U.K. study the
prevalence of coeliac disease was 240 per 100,000, i.e., eight times higher than that of DH. The same 8:1
ratio was calculated in the Finnish study, where the national prevalence of coeliac disease was 661 per
100,000 [38]. Nevertheless, DH is evidently the most common extraintestinal manifestation of coeliac
disease [42].
The Social Insurance Institution of Finland maintains a nationwide register of adults with coeliac
disease and DH. In 2003, it included a total of 18,538 patients, of whom 3121 (17%) had DH [28].
When we compared the annual numbers of new cases in five-year periods from 1980 to 2003, it was
evident that in the first period patients with coeliac disease only slightly outnumbered those with
DH (Figure 2). After the first period, the annual number of DH patients slowly decreased, whereas
the number of coeliac disease patients continuously increased. In the ten-year period of 2005–2014,
the proportion of newly diagnosed patients with DH had decreased to only 4% [43] (Figure 2).
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Importantly, a Finnish cohort study [18] and a U.K. register study [19] covering time periods of 30
and 20 years, respectively, showed convincingly that the annual incidence rate of DH has decreased
significantly. This decrease was from 5.2 to 2.7 per 100,000 in the Finnish study and from 1.8 to 0.8 per
100,000 in the U.K. study. The opposite was true for coeliac disease; there was a maximum of a fourfold
increase in the incidence rate [19]. The reason for this seems to be an increasing awareness of mild
symptoms, the development of efficient serological screening tests, and the identification of special
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risk groups, such as family members [20,23]. Sero-epidemiological studies suggest that in addition to
the better recognition of coeliac disease, there has also been a true increase in the incidence in recent
decades [44,45].
The decreasing incidence rate of DH in Finland and the U.K., along with a simultaneous
rapid increase in coeliac disease, fits our hypothesis that subclinical, undiagnosed coeliac disease is
a prerequisite for the development of DH. In support of this hypothesis, we know of patients initially
diagnosed with coeliac disease who did not follow or only partially followed a GFD and subsequently
developed DH [46]. Moreover, adult patients with DH frequently have coeliac-type dental enamel
defects, which develop early in childhood as a result of malabsorption or immune alteration caused by
undiagnosed coeliac disease [47].
5. Pathogenesis of Dermatitis Herpetiformis: From Gut to Skin
In DH, pathognomonic granular IgA deposits in the papillary dermis have long been suspected
to derive from the gut. In 2002, Sárdy et al. [48] showed that the autoantigen for deposited cutaneous
IgA is epidermal transglutaminase (TG3). This is closely related, but not identical, to the tissue
transglutaminase (TG2) autoantigen specific for coeliac disease [49]. The TG2 enzyme is a target for
IgA class autoantibody deposition in the small bowel mucosa in classical and potential coeliac disease,
and in DH [36,37,50]. The TG3 protein has not been detected in the small bowel similarly to the TG2
enzyme, but epitope spreading is a possibility [51]. Recently, DH patients with the active disease have
been shown to secrete high levels of TG3 antibodies into the gut organ culture medium, and also have
TG3-antibody-positive cells in the small intestinal mucosa [52]. At present, a valid hypothesis is that
the immunopathogenesis of DH starts from hidden coeliac disease in the gut with a TG2, and possibly
also a TG3, autoantibody response and evolves into an immune complex deposition of high avidity
IgA TG3 antibodies together with the TG3 enzyme in the papillary dermis [48]. Further support for
this comes from GFD treatment results; TG3 and TG2 antibodies in the blood disappear with the
dietary treatment and, at the same time, the rash and small bowel heal [53]. In contrast, the IgA-TG3
aggregates in the skin disappear very slowly with GFD treatment [54]. This seems to be due to the
active TG3 enzyme in the aggregates resulting in covalent cross-linking of the complex to dermal
structures [55].
6. Long-Term Prognosis on a Gluten-Free Diet Treatment
A GFD is the treatment of choice for all patients with DH regardless of whether they have villous
atrophy in the small bowel [7,8,10]. It is important to know the long-term prognosis for DH because,
as in coeliac disease, the risk of non-Hodgkin’s lymphoma is significantly increased [56]. However,
a strict GFD for more than five years seems to protect against lymphoma [57]. In agreement with this,
our cohort of 476 patients with DH, where almost all patients adhered to a GFD, showed a significantly
increased lymphoma mortality rate during the first five years of follow-up, but not thereafter [39].
Unexpectedly, the same study showed that the standardized mortality rate (SMR 0.70) was statistically
significantly reduced in the GFD-treated DH patients compared to the general population. In a previous
study of 846 DH patients from the U.K. [40], the adherence to a GFD was only partly known, and the
mortality rate was slightly, but non-significantly, reduced (hazard ratio 0.93).
In contrast to the excellent long-term prognosis for DH, a meta-analysis of prospective studies on
coeliac disease found a significantly increased risk for all-cause (odds ratio 1.24) and non-Hodgkin’s
lymphoma (odds ratio 2.61) mortality [41]. A recent large register study from England could only
confirm the excess risk of deaths from non-Hodgkin’s lymphoma [58]. However, in coeliac disease
mortality studies, the adherence to a GFD has not been analyzed or was only partially known [41,59];
therefore, there is a particular need to examine the relationship between mortality rate and
dietary compliance.
There are studies suggesting that patients with coeliac disease on a GFD retain a reduced quality
of life compared to the general population [60,61]. Recently, we examined long-term GFD-treated
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patients with DH [62]. Their quality of life was comparable to that of the general population, whereas
it was reduced in the coeliac disease controls.
7. Concluding Remarks
DH is the most common extraintestinal clinical manifestation of coeliac disease; at present,
the prevalence ratio of the disorders is 1:8. The incidence of DH is decreasing, whereas the opposite is
true for coeliac disease. A valid current hypothesis is that subclinical coeliac disease is a prerequisite
for the development of DH. The reason why only some undiagnosed coeliac individuals develop
an itchy blistering rash with dermal IgA-TG3 deposits remains unknown. The markedly increased age
at diagnosis and less severe small bowel damage both in DH and coeliac disease suggests changes in
environmental factors, such as a lowered lifetime gluten load. The long-term prognosis of DH patients
on a GFD is excellent, which seems to be due to a strict adherence to the diet.
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